BioInvestor

Biotech Buying Binge About to Begin?

There are a couple of things happening that signal activity in this market. Major pharma needs a pipeline; emerging pharma has pipeline opportunities. Emerging pharma raised lots of cash at the end of the dot.com bubble--that cash is now showing up as pipeline. However, that cash is also running out. Emerging companies are, relatively speaking, inexpensive. It's the perfect time for big pharma to go on an M&A spree.